Thus, both this study [32] as well as previous studies in sepsis patients [16] suggest that endocan and p14 endocan fragment levels reflect different biological processes/characteristics; the results presented in Table S1 suggest that this is true also for patients with untreated acute leukemia and patients receiving intensive conventional antileukemic chemotherapy (i.e., therapy not including stem cell transplantation or new targeted therapies). Here, ESM1 is linked to acute leukemia.